Postoperative tolvaptan use in left ventricular assist device patients: The TOLVAD randomized pilot study.

Mark N Belkin Teruhiko ImamuraDaniel RodgersAnthony J KanelidisMichael P HenryTakeo FujinoViktoriya KaganKaren MeehanJustin OkrayShana CreightonColleen LaBuhnTae SongTakeyoshi OtaValluvan JeevanandamAnn B NguyenBen B ChungBryan A SmithSara KalantariJonathan GrinsteinNitasha SarswatSean P PinneyGabriel SayerGene KimNir Uriel

Published in: Artificial organs (2022)

TLV significantly increases urine output, with nominal improvement in Na level, in hyponatremic post-operative LVAD patients without adversely impacting renal function.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
left ventricular assist device
chronic kidney disease
prognostic factors
peritoneal dialysis
randomized controlled trial
open label
clinical trial
atrial fibrillation